In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Co. PLC

www.perrigo.com

Latest From Perrigo Co. PLC

Mallinckrodt’s Phase III Kidney Failure Trial Hits Primary Endpoint

The data position Mallinckrodt to file for US FDA approval of terlipressin early next year. Mallinckrodt thinks the drug could generate sales of $300m a year, helping it to mitigate its challenges.

Clinical Trials Companies

Perrigo Remains Committed To Splitting Off Prescription Despite Delay

Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.

Strategy Sales & Earnings

Infant Formula Woes Turn Perrigo's Q2 Sour Despite Solid Americas’ OTC Sales

Perrigo reports 4% Q2 sales growth for OTC drugs in the Americas region was offset by nearly 15% drop in infant formula sale. Total consumer sales in the Americas slipped 2.5% to $582m, but CEO Murray Kessler says brighter days are ahead on benefits from Ranir oral care acquisition.

Sales & Earnings OTC Drugs

Perrigo Rapped Over Solpadeine Claim in UK, While Cleared Of Wrongdoing In Spanish XLS Ad

Perrigo has found itself in hot water with the UK's MHRA over claims made on the website of its Solpadeine pain-relief brand. Meanwhile, the company has been exonerated after complaints against a TV ad to promote its XLS weight-loss brand proved to be unfounded.
Ad Complaints Spain
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register